Manufacturing and Legal Woes Mount for Novo Nordisk

Legal Setback Compounds Regulatory Pressure

Novo Nordisk finds itself navigating one of its most challenging periods, as the Danish pharmaceutical giant contends with a rapidly escalating situation. A significant legal defeat and a severe regulatory sanction from the U.S. Food and Drug Administration (FDA) have converged, creating a perfect storm for the maker of Ozempic. As CEO Mike Doustdar implements aggressive countermeasures, the flow of negative developments continues, raising questions about the company’s ability to arrest its downward trajectory.